

Version 2.0

Revision Date: 10-28-2022

Date of last issue: 02-10-2020 Date of first issue: 04-18-2019

SECTION 1. IDENTIFICATION

Product name	:	HERCEPTIN(R) Vials (150 mg)	
Product code	:	00010080222		
Common name(s), syno- nym(s) of the substance	:	HERCEPTIN lyophilized Vials recombinant humanised monor with excipients	clonal antibody (Trastuzumab)	
Manufacturer or supplier's o	deta	ails		
Company name of supplier	:	Genentech, Inc.		
Address	:	1 DNA Way South San Francisco, CA 9408 USA	30	
Telephone E-mail address Emergency telephone	:	001-(650) 225-1000 info.sds@roche.com		
Emergency telephone num- ber	:	US Chemtrec phone	(800)-424-9300	
Recommended use of the chemical and restrictions on use				
Recommended use	:	Formulated pharmaceutical act	tive substance	
Restrictions on use	:	For professional users only.		

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)			
Combustible dust			
GHS label elements Signal Word	: Warning		
Hazard Statements	: May form combustible dust concentrations in air.		
Other hazards None known.			

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Trastuzumab	180288-69-1	51.31
Trehalose (D+)-), 2H2O	6138-23-4	46.6

Version 2.0	Revision Date 10-28-2022		 sue: 02-10-2020 sue: 04-18-2019
L-Histidine m	onohydrochloride mo-	5934-29-2	1.15

L-Histidine monohydrochloride mo- nohydrate	5934-29-2	1.15
L-Histidine	71-00-1	0.74
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.	9005-64-5	0.2

SECTION 4. FIRST AID MEASURES

General advice	:	Do not leave the victim unattended.
If inhaled	:	Move to fresh air. If unconscious, place in recovery position and seek medical advice. If symptoms persist, call a physician.
In case of skin contact	:	If on skin, rinse well with water.
In case of eye contact	:	Immediately flush eye(s) with plenty of water. Remove contact lenses. Protect unharmed eye. If eye irritation persists, consult a specialist.
If swallowed	:	Keep respiratory tract clear. Do not give milk or alcoholic beverages. Never give anything by mouth to an unconscious person. If symptoms persist, call a physician. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed	:	None known.
Notes to physician	:	The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment.
Specific hazards during fire fighting	:	No information available.
Hazardous combustion prod- ucts	:	In case of fire hazardous decomposition products may be produced such as: Carbon monoxide Nitrogen oxides (NOx) Carbon oxides Gaseous hydrogen chloride (HCI).
Further information	:	Standard procedure for chemical fires. Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment.

HERCEPTIN(R) Vials (150 mg)

Version 2.0	Revision D 10-28-2022		
Special protective e for fire-fighters	quipment :	Vear self-contained breathing appara necessary.	tus for firefighting if

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Avoid dust formation.
Environmental precautions	:	Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion	:	Provide appropriate exhaust ventilation at places where dust is formed.
Advice on safe handling	:	For personal protection see section 8. Smoking, eating and drinking should be prohibited in the ap- plication area.
Conditions for safe storage	:	Store between +2°C and +8C. Store protected from light
		Electrical installations / working materials must comply with the technological safety standards.
Further information on stor- age conditions	:	See label, package insert or internal guidelines
Materials to avoid	:	No materials to be especially mentioned.
Further information on stor- age stability	:	No decomposition if stored and applied as directed.
Packaging material	:	Suitable material: glass

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Trastuzumab	180288-69-1	IOEL	0.1 mg/m3	Roche In- dustrial Hy- giene Com- mittee (RIHC)



HERCEPTIN(R) Vials (150 mg) Date of last issue: 02-10-2020 Version Revision Date: 2.0 10-28-2022 Date of first issue: 04-18-2019 **Engineering measures** No data available : Personal protective equipment Respiratory protection : No personal respiratory protective equipment normally required. Hand protection In case of contact through splashing: Material Nitrile rubber : Break through time > 30 min : Glove thickness : > 0.11 mm In case of full contact: Material butyl-rubber : > 480 min Break through time : Glove thickness > 0.4 mm : Remarks : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly. Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly. Eye protection Safety glasses : Skin and body protection Protective suit : Hygiene measures Handle in accordance with good industrial hygiene and safety : practice.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: solid, (lyophilized)
Color	: off-white
Odor	: Not applicable
Odor Threshold	: Not applicable
рН	: Not applicable
Melting point/range	: No data available
Boiling point/boiling range	: No data available
Flash point	: does not flash
Evaporation rate	: No data available

Version 2.0	Revision Date: 10-28-2022	Date of last issue: 02-10-2020 Date of first issue: 04-18-2019
Self-ignition	: No data avai	lable
Upper explosion limit / flammability limit	Upper : No data avai	lable
Lower explosion limit / flammability limit	Lower : No data avai	lable
Vapor pressure	: No data avai	lable
Relative vapor density	: Not applicab	le
Relative density	: No data avai	lable
Solubility(ies) Water solubility	: completely s	oluble
Solubility in other so	olvents : No data avai	lable
Partition coefficient: n- octanol/water	: No data avai	lable
Autoignition temperatur	re : No data avai	lable
Decomposition tempera	ature : No data avai	lable
Viscosity Viscosity, dynamic	: Not applicab	le
Viscosity, kinematic	: Not applicab	le
Oxidizing properties	: No data avai	lable

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	No dangerous reaction known under conditions of normal use.
Chemical stability	:	Stable under normal conditions. Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Pro- cess Safety; during decomposition no flammable gas, no or- ganic peroxide and no oxidising substances are created Does not contain any antimicrobial preservative; therefore, care must be taken to ensure the sterility of the prepared solu- tion
Possibility of hazardous reac- tions	:	Stable under recommended storage conditions. No hazards to be specially mentioned.
Conditions to avoid	:	Heat.
Incompatible materials	:	No data available
Hazardous decomposition products	:	No data available

HERCEPTIN(R) Vials (150 mg)

Version 2.0 Revision Date: 10-28-2022

Date of last issue: 02-10-2020 Date of first issue: 04-18-2019

SECTION 11. TOXICOLOGICAL INFORMATION

Acute toxicity

Not classified based on available information.

Components:

Trastuzumab:

Acute oral toxicity	:	Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of	:	Maximum tolerated dose (Mouse): > 94 mg/kg
administration)		Application Route: i.v.

Trehalose (D+)-), 2H2O:

Acute oral toxicity : LD50 (Rat): 16,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

- **IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
- **OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.
- **NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Trastuzumab:

Effects on fetal development	:	Result: Parenteral administration to pregnant women can cau-
		se fetal harm



HERCEPTIN(R) Vials (150 mg)

Version 2.0

Revision Date: 10-28-2022

Date of last issue: 02-10-2020 Date of first issue: 04-18-2019

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Aspiration toxicity

Not classified based on available information.

Further information

Components:

Trastuzumab:

Remarks

: anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described with other monoclonal antibodies

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Trehalose (D+)-), 2H2O:		
Toxicity to fish	:	LC50 (Danio rerio (zebra fish)): > 100 mg/l Exposure time: 96 h Test Type: static test
Toxicity to fish (Chronic tox- icity)	:	NOEC (Danio rerio (zebra fish)): 100 mg/l Exposure time: 96 d
Ecotoxicology Assessment		
Acute aquatic toxicity	:	This product has no known ecotoxicological effects.
Chronic aquatic toxicity	:	This product has no known ecotoxicological effects.
Toxicity Data on Soil	:	Not expected to adsorb on soil.
Other organisms relevant to the environment	:	No data available

Persistence and degradability

Components:

Trastuzumab: Biodegradability : Result: Readily biodegradable. Biodegradation: 65 % Exposure time: 14 d Method: OECD Test Guideline 301F GLP: yes

Result: Globular proteins are generally well biodegradable

Version 2.0

Revision Date: 10-28-2022

Date of last issue: 02-10-2020 Date of first issue: 04-18-2019

Trehalose (D+)-), 2H2O:

$\frac{1}{1} \frac{1}{1} \frac{1}$		
Biodegradability	:	aerobic Inoculum: activated sludge, non-adapted Biochemical oxygen demand Result: Readily biodegradable. Biodegradation: 73 % Method: OECD Test Guideline 301A Remarks: The 10 day time window criterion is not fulfilled. aerobic Inoculum: activated sludge, non-adapted Dissolved organic carbon (DOC) Result: Readily biodegradable. Biodegradation: 98 % Method: OECD Test Guideline 301A
Bioaccumulative potential		
Components:		
Trastuzumab:		
Partition coefficient: n- octanol/water	:	Remarks: No data available
Trehalose (D+)-), 2H2O:		
Partition coefficient: n- octanol/water	:	Remarks: No data available
Mobility in soil No data available		
Other adverse effects		
Product:		
Ozone-Depletion Potential	:	Regulation: 40 CFR Protection of Environment; Part 82 Pro- tection of Stratospheric Ozone - CAA Section 602 Class I Substances Remarks: This product neither contains, nor was manufac- tured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).
Components:		
Trastuzumab:		
Additional ecological infor- mation	•	Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic poten- tial is to be expected

Version 2.0 Revision Date: 10-28-2022

Date of last issue: 02-10-2020 Date of first issue: 04-18-2019

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal	methods
----------	---------

Waste from residues	:	Can be disposed as waste water, when in compliance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

Domestic regulation

49 CFR Not regulated as a dangerous good

Special precautions for user

Remarks

Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

·

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	: Combustible dust
----------------------	--------------------

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Version 2.0 Revision Date: 10-28-2022

Date of last issue: 02-10-2020 Date of first issue: 04-18-2019

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations

DSL

Massachusetts Right To Know

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know

Trastuzumab Trehalose (D+)-), 2H2O 180288-69-1 6138-23-4

Maine Chemicals of High Concern

Product does not contain any listed chemicals

Vermont Chemicals of High Concern

Product does not contain any listed chemicals

Washington Chemicals of High Concern

Product does not contain any listed chemicals

The ingredients of this produ	ıct	are reported in the following inventories:
AIIC	:	Not in compliance with the inventory

This product contains the following components that are not on the Canadian DSL nor NDSL.

Trastuzumab

L-Histidine monohydrochloride monohydrate

- NZIoC : On the inventory, or in compliance with the inventory
- ENCS : Not in compliance with the inventory
- ISHL : Not in compliance with the inventory
- KECI : Not in compliance with the inventory
- PICCS : Not in compliance with the inventory


ntory.
;

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION



HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% response; EMS - Imergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% response; EMS - Imergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% response; EMS - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemical Substances in Standardization; KECI - Korea Exist

Version 2.0

Revision Date: 10-28-2022

Date of last issue: 02-10-2020 Date of first issue: 04-18-2019

cals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date

10-28-2022

:

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 2104